SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

NCT05814354 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: SHR-A1811
DRUG: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.